Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
4.290
+0.170 (4.13%)
At close: Feb 27, 2026, 4:00 PM EST
4.250
-0.040 (-0.93%)
After-hours: Feb 27, 2026, 7:56 PM EST
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
66.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 196.00K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 30.91M |
| ImmuCell | 27.77M |
| TScan Therapeutics | 8.42M |
| NeurAxis | 3.36M |
| Spruce Biosciences | 697.00K |
| Mereo BioPharma Group | 500.00K |
| InflaRx | 73.73K |
GRCE News
- 3 days ago - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 16 days ago - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 4 months ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 5 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire
- 5 months ago - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - GlobeNewsWire